Koyalta Donato, Mboumba Bouassa Ralph-Sydney, Maiga Almoustapha Issiaka, Balde Aliou, Bagendabanga Jules Bashi, Alinity Almahdy Ag, Veyer David, Péré Hélène, Bélec Laurent
Centre Hospitalo-Universitaire Gabriel Touré, Bamako, Bamako, Mali.
Faculté des Sciences de la Santé Humaine de N'Djamena, N'Djamena, Chad.
Infect Agent Cancer. 2021 Jul 1;16(1):51. doi: 10.1186/s13027-021-00385-0.
High-risk human papillomavirus (HR-HPV) anal infection is a major problem among men who have sex with men (MSM) living in sub-Saharan Africa. The prevalence of anal HR-HPV infection and associated risk factors were estimated in a cross-sectional study in MSM living in Bamako, Mali.
MSM consulting at sexual health center of the National NGO Soutoura, Bamako, were prospectively included. Sociodemographic and clinical-biological data were collected. HPV detection and genotyping were performed from anal swabs using multiplex real-time PCR. Risk factors associated with anal HPV infection were assessed by logistic regression analysis.
Fifty MSM (mean age, 24.2 years; range, 18-35) of which 32.0% were infected with HIV-1, were prospectively included. The overall prevalence of anal HPV infection of any genotypes was 70.0% (35/50) with 80.0% (28/35) of swabs positive for HR-HPV. HR-HPV-58 was the most detected genotype [13/35 (37.1%)], followed by HR-HPV-16 and low-risk (LR)-HPV-6 [12/35 (34.2%)], LR-HPV-40 [10/35 (28.6%)], LR-HPV-11 [9/35 (25.7%)], HR-HPV-51 [8/35 (22.8%)], HR-HPV types 18 and 39 [7/35 (20.0%)] and LR-HPV-43 [6/35 (17.1%)]. HR-HPV-52 and LR-HPV-44 were detected in lower proportions [5/35 (14.3%) and 4/35 (11.4%), respectively]. LR-HPV-42, LR-HPV-54, HR-HPV-31 and HR-HPV-35 were detected in very low proportions [3/35 (8.5%)]. Multiple HR-HPV infections were diagnosed in one-third of anal samples [16/50 (32.0%)], including around half of HR-HPV-positive anal swabs [16/35 (45.7%)]. More than half [27/50 (54.0%)] swabs were infected by at least one of HPV genotypes targeted by Gardasil-9® vaccine, including a majority of vaccine HR-HPV [22/50 (44.0%)]. In multivariate analysis, participation to sex in group was associated with anal infection by multiple HPV (aOR: 4.5, 95% CI: 1.1-18.1%; P = 0.032), and HIV-1 infection was associated with anal shedding of multiple HR-HPV (aOR: 5.5, 95% CI: 1.3-24.5%; P = 0.024).
These observations indicate that the MSM community living in Bamako is at high-risk for HR-HPV anal infections, with a unique epidemiological HPV genotypes profile and high prevalence of anal HPV covered by the Gardasil-9® vaccine. Scaling up prevention strategies against HPV infection and related cancers adapted to this highly vulnerable MSM community should be urgently prioritized with innovative interventions.
高危型人乳头瘤病毒(HR-HPV)肛门感染是撒哈拉以南非洲男男性行为者(MSM)中的一个主要问题。在马里巴马科的一项针对男男性行为者的横断面研究中,估计了肛门HR-HPV感染的患病率及相关危险因素。
前瞻性纳入在巴马科国家非政府组织Soutoura性健康中心咨询的男男性行为者。收集社会人口统计学和临床生物学数据。使用多重实时PCR从肛门拭子中进行HPV检测和基因分型。通过逻辑回归分析评估与肛门HPV感染相关的危险因素。
前瞻性纳入了50名男男性行为者(平均年龄24.2岁;范围18 - 35岁),其中32.0%感染了HIV-1。任何基因型的肛门HPV感染总体患病率为70.0%(35/50),HR-HPV阳性拭子占80.0%(28/35)。HR-HPV-58是检测到最多的基因型[13/35(37.1%)],其次是HR-HPV-16和低危(LR)-HPV-6[12/35(34.2%)]、LR-HPV-40[10/35(28.6%)]、LR-HPV-11[9/35(25.7%)]、HR-HPV-51[8/35(22.8%)]、HR-HPV 18和39型[7/35(20.0%)]以及LR-HPV-43[6/35(17.1%)]。HR-HPV-52和LR-HPV-44的检测比例较低[分别为5/35(14.3%)和4/35(11.4%)]。LR-HPV-42、LR-HPV-54、HR-HPV-31和HR-HPV-35的检测比例极低[3/35(8.5%)]。三分之一的肛门样本诊断为多重HR-HPV感染[16/50(32.0%)],包括约一半的HR-HPV阳性肛门拭子[16/35(45.7%)]。超过一半[27/50(54.0%)]的拭子感染了至少一种九价人乳头瘤病毒重组疫苗(Gardasil-9®)针对的HPV基因型,其中大多数是疫苗HR-HPV[22/50(44.0%)]。在多变量分析中,参与群交与多重HPV肛门感染相关(调整后比值比:4.5,95%置信区间:1.1 - 18.1%;P = 0.032),HIV-1感染与多重HR-HPV肛门脱落相关(调整后比值比:5.5,95%置信区间:1.3 - 24.5%;P = 0.024)。
这些观察结果表明,生活在巴马科的男男性行为者群体面临HR-HPV肛门感染的高风险,具有独特的HPV基因型流行病学特征,且九价人乳头瘤病毒重组疫苗(Gardasil-9®)覆盖的肛门HPV患病率较高。应通过创新干预措施,紧急优先扩大针对该高度脆弱男男性行为者群体的HPV感染及相关癌症的预防策略。